Tigecycline - Resistant Pathogen Program
 |
Phase 3, open-label, noncomparative study of Tigecycline's (Wyeth) efficacy in treating bactermia secondary to |
non-Pseudomonal gram negative bacteria and side-effects.
|
Phase 3, multicenter, double-blinded, randomized (3:1) comparative study of Tigecycline's (Wyeth) efficacy in treating |
bacteremia secondary to MRSA and/or VRE and side-effects versus Linezolid.
Please contact Heather McNutt (daytime #6476) or Dr. Munasinghe (nighttime #3681) if you have a patient with MRSA, VRE, or gram negative bacteremia.
ACUITY Trial
|
Randomized comparison of Angiomax (bivalirudin) versus UFH in patients undergoing early invasive management for |
acute coronary syndromes without ST-segment elevation/
Please contact Heather McNutt (daytime-#6476) or Dr. Mahmood (anytime #11586) if you have a patient with a diagnosis consistent with unstable angina or NSTEMI.